Protalex, Inc.
75 articles about Protalex, Inc.
-
Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the European Hematology Association 23rd Annual Meeting
6/15/2018
Protalex’s lead drug candidate PRTX-100, is a highly purified form of staphylococcal protein A.
-
Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis
6/12/2018
Findings Support Advancement of PRTX-100 into its Third Clinical Indication.
-
Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting
5/17/2018
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) (PRTX-100-203 Study) will be presented at the upcoming European Hematology Association (EHA) 23rd Annual Meeting being held in Stockholm from June 14-17, 2018
-
Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia
4/9/2018
Additional study sites opened in the U.K. for the 202 Study
-
Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase Ib Study of PRTX-100 in Immune Thrombocytopenia
1/18/2018
Protalex today announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), the Company has initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.
-
Protalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia
10/26/2017
Protalex announces that preclinical data showing its lead drug candidate PRTX-100 increases blood platelet counts in a murine model of immune thrombocytopenia (ITP) were published in the recent issue of the peer-reviewed journal, British Journal of Haematology.
-
Protalex Doses First Patient In Third Cohort Of European Phase Ib Study Of PRTX-100 In ITP
8/29/2017
-
Protalex Awarded Grant From FDA Office Of Orphan Products Development To Foster Clinical Development Of PRTX-100 For The Treatment Of Immune Thrombocytopenia
8/17/2017
-
Protalex Completes Data Analysis Of Second Dose Cohort Of U.S. Phase I/II Study Of PRTX-100 In ITP
8/1/2017
-
Protalex Issues Letter To Shareholders
6/7/2017
-
Protalex Significantly Strengthens Global Intellectual Property Portfolio For Proprietary Immunomodulatory Therapeutic
3/13/2017
-
Protalex Provides Update On U.S. And EU Studies Of PRTX-100 To Treat Immune Thrombocytopenia
2/21/2017
-
Protalex, Inc. Receives Positive Interim Review From Independent Safety Monitoring Committee In Its European Phase Ib Study Of PRTX-100 To Treat Immune Thrombocytopenia
5/2/2016
-
Protalex, Inc. Announces Preliminary Findings From Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients
4/25/2016
-
Four Small-Cap Biotechs Investors Should Take a Look at
3/15/2016
-
Protalex, Inc. Receives Positive Interim Review From Independent Safety Monitoring Committee In Its U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia
2/29/2016
-
Protalex, Inc. Announces First Patient Dosed In European Phase Ib Study Of PRTX-100 For Immune Thrombocytopenia
1/7/2016
-
Protalex, Inc. Announces First Patient Dosed In U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia
11/23/2015
-
Protalex, Inc. Announces Presentation Of Preclinical Data With PRTX-100 Supporting Treatment Of Immune Thrombocytopenia At The American Society of Hematology 57th Annual Meeting And Exposition
11/11/2015
-
Protalex, Inc. Announces Regulatory Approval To Initiate Phase Ib Trial Of PRTX-100 To Treat Immune Thrombocytopenia In France
10/5/2015